United Therapeutics (UTHR) Non-Current Debt (2010 - 2024)

United Therapeutics has disclosed Non-Current Debt across 13 years of filings, most recently posting $100.0 million for Q2 2024.

• Non-Current Debt for Q2 2024 came in at $100.0 million, down 87.5% year-over-year; the trailing twelve-month figure through Jun 2024 was $100.0 million (down 87.5% YoY), and the FY2023 annual result was $300.0 million, down 62.5% from the prior year.
• Non-Current Debt came in at $100.0 million for Q2 2024 at United Therapeutics, down from $200.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $800.0 million in Q1 2020 to a low of $100.0 million in Q2 2024.
• The 5-year median for Non-Current Debt is $800.0 million (2020), against an average of $683.3 million.
• Across the five-year window, Non-Current Debt jumped 33.33% in 2020 and sank 87.5% in 2024, its largest moves.
• United Therapeutics' Non-Current Debt stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then slumped by 62.5% to $300.0 million in 2023, then slumped by 66.67% to $100.0 million in 2024.
• The last three Non-Current Debt figures came in at $100.0 million (Q2 2024), $200.0 million (Q1 2024), and $300.0 million (Q4 2023), per Business Quant data.